Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication

Vascular Medicine

Volumn 6, Issue 4, 2001, Pages 235-239

  Cooper Jr , Leslie T ^a   Hiatt, William R ^a   Creager, Mark A ^a   Regensteiner, Judith G ^a   Casscells, Ward ^a   Isner, Jeffrey M ^a   Cooke, John P ^a   Hirsch, Alan T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Claudication; Growth substances; Trials

Indexed keywords

GROWTH PROMOTOR; PLACEBO; PROTEIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ANGIOGENESIS; APPETITE DISORDER; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EXERCISE; EXERCISE TEST; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; LIMB BLOOD FLOW; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; SYMPTOM; TREADMILL EXERCISE; WALKING;

EID: 0035725781     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836X0100600406     Document Type: Article

References (21)

1. The prevalence of peripheral arterial occlusive disease in a defined population
2. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index
3. Cilostazol has beneficial effects in the treatment of intermittent claudication
4. Management of intermittent claudication with pentoxyfilline: Meta-analysis of randomized controlled trials
5. Ginkgo biloba extract for the treatment of intermittent claudication: A meta analysis of randomized trials
6. European multicenter study on propionyl-L-carnitine in intermittent claudication
7. Nutritional therapy for peripheral arterial occlusive disease: A double-blind, placebo-controlled, randomized trial of HeartBar
8. The effect of exercises on walking distance of patients with intermittent claudication: A study of randomized clinical trials
9. Superiority of treadmill walking exercises versus strength training for patients with peripheral arterial occlusive disease
10. Quality of life in patients with intermittent claudication
11. Impact of intermittent claudication on quality of life
12. Treatment of intermittent claudication: The impact on quality of life
13. Angiogenesis
14. Enhanced angiogenesis and growth of collaterals by administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor
15. Clinical trials for claudication: Assessment of exercise performance, functional status, and clinical endpoints
16. Exercise training improves functional status in patients with peripheral arterial disease
17. Experience with the preclinical assessment of basic fibroblast growth factor
18. Effects of basic fibroblast growth factor on lower extremity blood flow in patients with intermittent claudication
19. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
20. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
21. Reduction in stress myocardial ischemia by basic fibroblast growth factor (r-FGF2) in severe ischemic heart disease